FDA Approval Alert: The Need-to-Know | Isatuximab/VRd in Transplant-Ineligible NDMM

In September 2024, the FDA approved isatuximab-irfc plus bortezomib, lenalidomide, and dexamethasone (Isa-VRd) as a treatment for patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant.

Isatuximab plus VRd triplet therapy did not significantly increase toxicity in patients with transplant-ineligible multiple myeloma in the IMROZ trial.
Isatuximab Quadruplet Therapy Appears Well Tolerated in Multiple Myeloma
Video
Oct 2, 2024 8:00 PM
Isatuximab plus VRd triplet therapy did not significantly increase toxicity in patients with transplant-ineligible multiple myeloma in the IMROZ trial.
Isatuximab quadruplet therapy for patients with multiple myeloma prolonged progression-free survival when compared with VRd triplet therapy.
Isatuximab Quadruplet Therapy Shows PFS Advantage in Multiple Myeloma
Video
Oct 2, 2024 6:00 PM
Isatuximab quadruplet therapy for patients with multiple myeloma prolonged progression-free survival when compared with VRd triplet therapy.
Findings from the phase 3 IMROZ trial support the FDA approval of the combination therapy for newly diagnosed not eligible for ASCT multiple myeloma.
FDA Approves Isatuximab/VRd in Newly Diagnosed Multiple Myeloma
Article
Sep 20, 2024 7:57 PM
Findings from the phase 3 IMROZ trial support the FDA approval of the combination therapy for newly diagnosed not eligible for ASCT multiple myeloma.